CTLA-4 inhibitors (e.g. Ipilimumab and Tremelimumab), PD-1 inhibitors (e.g. Pembrolizumab, Nivolumab, and Cemiplimab) and PD-L1 inhibitors (e.g. Atezolizumab, Durvalumab, and Avelumab) are widely used alone or in combination to treat different types of cancer, including melanoma, non-small cell lung cancer, bladder cancer, renal cell carcinoma, head and neck squamous cell carcinoma, among others (20). This evidence concerns the gene CD274 and cancer.